SCHEMBL5575310

SCHEMBL5575310

O=[C]C(O)C(O)CO

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7718568 1.00
SCHEMBL9811639 0.82 LMNA (0.53)
SCHEMBL17200647 0.82 LMNA (0.53)
SCHEMBL14937404 0.80 LMNA (0.58)
SCHEMBL23647592 0.80 LMNA (0.58)
SCHEMBL8768308 0.75 LMNA (0.42)
SCHEMBL6373695 0.73
SCHEMBL10427686 0.71
SCHEMBL10427707 0.71
SCHEMBL667678 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070244055-A1 Conjugates useful in the treatment of prostate cancer BRADY STEPHEN F 2007-10-18 US disclosed
US-20070129309-A1 Conjugates useful in the treatment of prostate cancer BRADY STEPHEN F 2007-06-07 US disclosed
US-20070021350-A1 Conjugates useful in the treatment of prostate cancer BRADY STEPHEN F 2007-01-25 US disclosed
US-20060148718-A1 Conjugates useful in the treatment of prostate cancer BRADY STEPHEN F 2006-07-06 US disclosed
EP-1545572-A4 CONJUGATES ACTIVATED BY CELL SURFACE PROTEASES AND THERAPEUTIC USES THEREOF DENDREON CORP (US) 2006-04-12 EP disclosed
EP-1545572-A2 CONJUGATES ACTIVATED BY CELL SURFACE PROTEASES AND THERAPEUTIC USES THEREOF Dendreon Corporation (US) 2005-06-29 EP disclosed
US-20050119166-A1 Conjugates useful in the treatment of prostate cancer BRADY STEPHEN F (US) 2005-06-02 US disclosed
US-20040081659-A1 Conjugates useful in the treatment of prostate cancer MERCK & CO., INC. 2004-04-29 US disclosed
US-20040058857-A1 Method of treating cancer YAO SIU-LONG (US) 2004-03-25 US disclosed
US-20040001801-A1 Conjugates activated by cell surface proteases and therapeutic uses thereof CORVAS INTERNATIONAL, INC. 2004-01-01 US disclosed
EP-1036093-A1 CONJUGATES USEFUL IN THE TREATMENT OF PROSTATE CANCER Merck & Co., Inc. (US) 2000-09-20 EP disclosed
EP-1009420-A1 CONJUGATES USEFUL IN THE TREATMENT OF PROSTATE CANCER Merck & Co., Inc. (US) 2000-06-21 EP disclosed
US-5998362-A OLIGOPEPTIDES, HAVING AMINO ACID SEQUENCES THAT ARE SELECTIVELY PROTEOLYTICALLY CLEAVED BY FREE PROSTATE SPECIFIC ANTIGEN (PSA), HYDROPHILIC OLIGOPEPTIDE BLOCKING GROUPS MERCK & CO., INC. (US) 1999-12-07 US disclosed
EP-0942754-A2 CONJUGATES USEFUL IN THE TREATMENT OF PROSTATE CANCER Merck & Co., Inc. (US) 1999-09-22 EP disclosed
US-5948750-A OLIGOPEPTIDES, HAVING AMINO ACID SEQUENCES THAT ARE SELECTIVELY PROTEOLYTICALLY CLEAVED BY FREE PROSTATE SPECIFIC ANTIGEN (PSA) AND KNOWN CYTOTOXIC AGENTS ARE DISCLOSED. SUCH CONJUGATES ARE USEFUL IN THE TREATMENT OF PROSTATIC CANCER AND MERCK & CO., INC. (US) 1999-09-07 US disclosed
EP-0926955-A1 CONJUGATES USEFUL IN THE TREATMENT OF PROSTATE CANCER Merck & Co., Inc. (US) 1999-07-07 EP disclosed
WO-1999028345-A1 CONJUGATES USEFUL IN THE TREATMENT OF PROSTATE CANCER MERCK & CO., INC. (US) 1999-06-10 WO disclosed
WO-1999002175-A1 CONJUGATES USEFUL IN THE TREATMENT OF PROSTATE CANCER MERCK & CO., INC. (US) 1999-01-21 WO disclosed
WO-1998018493-A2 CONJUGATES USEFUL IN THE TREATMENT OF PROSTATE CANCER MERCK & CO., INC. (US) 1998-05-07 WO disclosed
WO-1998010651-A1 CONJUGATES USEFUL IN THE TREATMENT OF PROSTATE CANCER MERCK & CO., INC. (US) 1998-03-19 WO disclosed